PolyPhotonix, a bio-photonic research and development company, designs, develops and manufactures non-invasive photonic based medical devices. They have been researching causes and treatments of eye disease for over 6 years.
Diabetic Retinopathy is caused by changes in the blood vessels of the retina. New fragile blood vessels start to grow and often leak blood and fluid. 90% of people with Type 1 diabetes will develop Diabetic Retinopathy within 10 years. 67% of people with Type 2 diabetes will develop Diabetic Retinopathy within 10 years.
PolyPhotonix was new to working with the NHS. The company had developed a light therapy mask for the prevention andtreatment of diabetic retinopathy, a condition which costs the NHS more than £1 billion a year. Current treatment costs up to £10,000 per patient for each eye; the Polyphotonix sleep mask costs £250 for 12 weeks treatment.
PolyPhotonix needed help to find practitioners and patients for a clinical study into the efficacy of the Noctura 400 sleep mask, a revolutionary treatment for diabetic retinopathy and diabetic macular oedema (DMO).
Whilst working as Commercial Director for the SW AHSN Paula Varndell-Dawes assisted Polyphotonix to recruit local sites for their clinical study into Noctura 400 treatment for Diabetic Retinopathy to demonstrate and evaluate the care pathway for NHS adoption (CANDLE).